New obesity drug HDM1005 enters Mid-Stage trial
NCT ID NCT06886126
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing an investigational drug called HDM1005 for weight loss in 240 adults with obesity who do not have diabetes. Participants receive weekly injections of either the drug or a placebo for 22 weeks. The main goal is to see how much body weight they lose and whether the drug is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HDM1005 injection
- What this could lead to
- If successful, this could lead to a new weight-loss treatment for people with obesity who do not have diabetes.
- What could go wrong
- This is an early Phase 2 trial with only 240 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?